These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28655451)

  • 1. Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trials.
    Beyer WEP; Palache AM; Boulfich M; Osterhaus ADME
    Vaccine; 2017 Jul; 35(33):4167-4176. PubMed ID: 28655451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.
    Skowronski DM; Janjua NZ; Sabaiduc S; De Serres G; Winter AL; Gubbay JB; Dickinson JA; Fonseca K; Charest H; Bastien N; Li Y; Kwindt TL; Mahmud SM; Van Caeseele P; Krajden M; Petric M
    J Infect Dis; 2014 Jul; 210(1):126-37. PubMed ID: 24446529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials.
    Moa AM; Chughtai AA; Muscatello DJ; Turner RM; MacIntyre CR
    Vaccine; 2016 Jul; 34(35):4092-4102. PubMed ID: 27381642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.
    Beran J; Peeters M; Dewé W; Raupachová J; Hobzová L; Devaster JM
    BMC Infect Dis; 2013 May; 13():224. PubMed ID: 23688546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
    Tinoco JC; Pavia-Ruz N; Cruz-Valdez A; Aranza Doniz C; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
    Vaccine; 2014 Mar; 32(13):1480-7. PubMed ID: 24486352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
    Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine.
    Reed C; Meltzer MI; Finelli L; Fiore A
    Vaccine; 2012 Mar; 30(11):1993-8. PubMed ID: 22226861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between vaccine adjuvant effect and pre-seasonal immunity. Systematic review and meta-analysis of randomised immunogenicity trials comparing squalene-adjuvanted and aqueous inactivated influenza vaccines.
    Beyer WEP; Palache AM; Reperant LA; Boulfich M; Osterhaus ADME
    Vaccine; 2020 Feb; 38(7):1614-1622. PubMed ID: 31879122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012.
    Heikkinen T; Ikonen N; Ziegler T
    Clin Infect Dis; 2014 Dec; 59(11):1519-24. PubMed ID: 25139969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004-2017.
    Puzelli S; Di Martino A; Facchini M; Fabiani C; Calzoletti L; Di Mario G; Palmieri A; Affanni P; Camilloni B; Chironna M; D'Agaro P; Giannecchini S; Pariani E; Serra C; Rizzo C; Bella A; Donatelli I; Castrucci MR;
    BMC Infect Dis; 2019 Nov; 19(1):990. PubMed ID: 31752738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quadrivalent versus trivalent influenza vaccine: clinical outcomes in two influenza seasons, historical cohort study.
    Shasha D; Valinsky L; Hershkowitz Sikron F; Glatman-Freedman A; Mandelboim M; Toledano A; Paran Y; Ben-Ami R; Goldman D
    Clin Microbiol Infect; 2020 Jan; 26(1):101-106. PubMed ID: 31108229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study.
    Milne GJ; Halder N; Kelso JK; Barr IG; Moyes J; Kahn K; Twine R; Cohen C
    Influenza Other Respir Viruses; 2016 Jul; 10(4):324-32. PubMed ID: 26663701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
    Greenberg DP; Robertson CA; Noss MJ; Blatter MM; Biedenbender R; Decker MD
    Vaccine; 2013 Jan; 31(5):770-6. PubMed ID: 23228813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
    Bai Y; Shi N; Lu Q; Yang L; Wang Z; Li L; Han H; Zheng D; Luo F; Zhang Z; Ai X
    Hum Vaccin Immunother; 2015; 11(7):1648-53. PubMed ID: 26083828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lineage-matched versus mismatched influenza B vaccine effectiveness following seasons of marginal influenza B circulation.
    Omer I; Rosenberg A; Sefty H; Pando R; Mandelboim M; Mendelson E; Keinan-Boker L; Glatman-Freedman A;
    Vaccine; 2022 Feb; 40(6):880-885. PubMed ID: 35016804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia.
    Jamotte A; Chong CF; Manton A; Macabeo B; Toumi M
    BMC Public Health; 2016 Jul; 16():630. PubMed ID: 27449665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of antibodies and humoral response after seasonal trivalent vaccination against influenza B lineages in an elderly population of Spain.
    Muñoz IS; Rello SR; Lejarazu RO
    Enferm Infecc Microbiol Clin (Engl Ed); 2018 Nov; 36(9):572-575. PubMed ID: 29179984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.